A
Acorda Therapeutics
A publicly traded biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders
At a glance
- Status
- Listed
- Listing
- IPO 2006
- Outcome tier
- Thoroughbred$100M+ revenue
News
Open roles
Acorda Therapeutics in the Town of Orangetown ecosystem
The Acorda Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- FVForward Ventures
- BCBayStar Capital
- SLSwiss Life
Series B and later7 investors entered at this stage
- AAABN AMRO
- EGEaston Capital Investment Group
- MLMerrill Lynch
- MBMPM BioImpact
JP Morgan- TSTVM Capital Life Science
- CPCross Atlantic Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
35 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Acorda Therapeutics was the backer or acquirer, 2012–2016. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
3 deals across Acorda Therapeutics's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Acorda Therapeutics's portfolio, mapped.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Acorda Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Acorda Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

